Zimmer Biomet Holdings, Inc. $ZBH Stake Reduced by Kingswood Wealth Advisors LLC

Kingswood Wealth Advisors LLC reduced its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 6.9% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,426 shares of the medical equipment provider’s stock after selling 179 shares during the quarter. Kingswood Wealth Advisors LLC’s holdings in Zimmer Biomet were worth $221,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in ZBH. Brighton Jones LLC bought a new position in shares of Zimmer Biomet in the fourth quarter worth $204,000. Farther Finance Advisors LLC grew its stake in shares of Zimmer Biomet by 33.9% in the first quarter. Farther Finance Advisors LLC now owns 7,300 shares of the medical equipment provider’s stock worth $820,000 after purchasing an additional 1,849 shares in the last quarter. GAMMA Investing LLC grew its stake in shares of Zimmer Biomet by 52.4% in the first quarter. GAMMA Investing LLC now owns 3,502 shares of the medical equipment provider’s stock worth $396,000 after purchasing an additional 1,204 shares in the last quarter. Assenagon Asset Management S.A. grew its stake in shares of Zimmer Biomet by 0.7% in the first quarter. Assenagon Asset Management S.A. now owns 28,692 shares of the medical equipment provider’s stock worth $3,247,000 after purchasing an additional 202 shares in the last quarter. Finally, CX Institutional grew its stake in shares of Zimmer Biomet by 7.4% in the first quarter. CX Institutional now owns 2,510 shares of the medical equipment provider’s stock worth $284,000 after purchasing an additional 174 shares in the last quarter. 88.89% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

ZBH has been the subject of several recent analyst reports. Redburn Partners set a $130.00 price target on Zimmer Biomet in a research note on Thursday, September 18th. Weiss Ratings reissued a “hold (c-)” rating on shares of Zimmer Biomet in a research note on Wednesday. Evercore ISI decreased their target price on Zimmer Biomet from $106.00 to $104.00 and set an “in-line” rating for the company in a research note on Tuesday, October 7th. Raymond James Financial raised their target price on Zimmer Biomet from $104.00 to $113.00 and gave the company an “outperform” rating in a research note on Friday, August 8th. Finally, Rothschild & Co Redburn started coverage on Zimmer Biomet in a research note on Thursday, September 18th. They set a “buy” rating and a $130.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, eight have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $112.67.

Zimmer Biomet Trading Down 2.6%

Shares of NYSE ZBH opened at $94.79 on Friday. Zimmer Biomet Holdings, Inc. has a 12 month low of $89.22 and a 12 month high of $114.72. The company has a market cap of $18.78 billion, a price-to-earnings ratio of 23.06, a P/E/G ratio of 2.18 and a beta of 0.67. The company has a quick ratio of 0.96, a current ratio of 1.87 and a debt-to-equity ratio of 0.54. The business has a fifty day simple moving average of $101.31 and a 200-day simple moving average of $98.25.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 EPS for the quarter, beating the consensus estimate of $1.98 by $0.09. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The business had revenue of $2.08 billion during the quarter, compared to the consensus estimate of $2.06 billion. During the same period in the prior year, the business posted $2.01 earnings per share. Zimmer Biomet’s revenue was up 7.0% compared to the same quarter last year. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Sell-side analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be issued a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 1.0%. The ex-dividend date of this dividend is Tuesday, September 30th. Zimmer Biomet’s dividend payout ratio is currently 23.36%.

Insider Activity at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,500 shares of the company’s stock in a transaction on Monday, September 8th. The stock was sold at an average price of $104.15, for a total transaction of $156,225.00. Following the completion of the sale, the senior vice president directly owned 6,833 shares of the company’s stock, valued at $711,656.95. This represents a 18.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 1.39% of the stock is currently owned by corporate insiders.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.